Clinical trial

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

NCT03830411

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Sintilimab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-03-13

PhasePHASE2

Conditions

Nonsquamous Non-Small Cell Lung Cancerunresolved

Interventions

SintilimabDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

Xin-Hua Xulead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03830411 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.